Section Arrow
FEMY.NASDAQ
- Femasys
(Financial Status)
Quotes are at least 15-min delayed:2025/12/31 16:25 EST
After Hours
Last
 0.58
+0.0038 (+0.66%)
Bid
0.5655
Ask
0.58
High 0.58 
Low 0.5762 
Volume 17.43K 
Regular Hours (Closed)
Last
 0.5762
+0.0032 (+0.56%)
Day High 
0.594 
Prev. Close
0.573 
1-M High
0.99 
Volume 
1.67M 
Bid
0.5655
Ask
0.58
Day Low
0.55 
Open
0.5756 
1-M Low
0.5395 
Market Cap 
34.09M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.75 
20-SMA 0.81 
50-SMA 0.8 
52-W High 1.8 
52-W Low 0.3067 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.69/-0.43
Enterprise Value
35.61M
Balance Sheet
Book Value Per Share
0.08
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.63M
Operating Revenue Per Share
0.02
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
AVTRAvantor11.46-0.01-0.09%11.55PE
After Hours 11.46 0 0.00%
BAXBaxter International19.11-0.19-0.98%140.32PE
After Hours 19.11 0 0.00%
WRBYWarby Parker21.79-0.23-1.04%-- 
After Hours 21.81 +0.02 +0.09%
EKSOEkso Bionics Holdings Inc8.64-1.94-18.34%-- 
After Hours 8.5 -0.14 -1.62%
XRAYDENTSPLY SIRONA11.43+0.03+0.26%-- 
After Hours 11.45 +0.02 +0.17%
Industry overview quotes are at least 15 minutes delayed
Business Description
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.